Business
AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound
AVEO Oncology, an LG Chem company (AVEO), and HiberCell, Inc. (HiberCell) announced today that the companies have entered into an exclusive development and option agreement to develop HiberCell's first-in-human human protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitor, HC-5404, alone and in combination with AVEO's potent and selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), FOTIVDA® (tivozanib). FOTIVDA is an anti-angiogenic agent ap
About this update from Lg Chem Ltd.
[{"type":"text","content":"– First-in-Human PERK inhibitor (HC-5404) to be developed in combination with AVEO's FOTIVDA® (tivozanib) for RCC –","length":119,"tagName":"p","attribs":{}},{"type":"text","content":"– AVEO obtains option to an exclusive license for the development, manufacturing, and commercialization of HC-5404 –","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, Nov. 4, 2025 /PRNewswire/ -- AVEO Oncology, an LG Chem company (AVEO), and HiberCell, Inc. (HiberCell) announced today that the companies have entered into an exclusive development and option agreement to develop HiberCell's first-in-human human protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitor, HC-5404, alone and in combination with AVEO's potent and selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), FOTIVDA® (tivozanib). FOTIVDA is an anti-angiogenic agent approved by the U.S. Food and Drug Administration in March of 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. Pre-clinical studies of HC-5404 in multiple solid tumor models, including gastric cancer and RCC, suggest the potential for enhanced anti-tumor efficacy when combined with an anti-angiogenic agent.","length":946,"tagName":"p"},{"type":"image","alt":"Aveo Oncology Logo (PRNewsfoto/AVEO, an LG Chem company)","displaySize":"","headline":null,"caption":"Aveo Oncology Logo (PRNewsfoto/AVEO, an LG Chem company)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":290,"url":"https://media.zenfs.com/en/prnewswire.com/f906b0069c5cb0825485ab6736838685"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dUU7xVSbtmylR_B..Oh6Iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUxMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f906b0069c5cb0825485ab6736838685","width":400,"height":290}},"href":"https://mma.prnewswire.com/media/2108096/Aveo_Oncology_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the terms of the agreement, AVEO is responsible for conducting initial stage clinical development. During the Phase 2 clinical trial, AVEO will have the option to obtain an exclusive license for the development, manufacturing, and commercialization of HC-5404 in all therapeutic indications wo...